PMID- 37944441 OWN - NLM STAT- MEDLINE DCOM- 20231207 LR - 20231217 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 169 DP - 2023 Dec 31 TI - Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats. PG - 115852 LID - S0753-3322(23)01650-5 [pii] LID - 10.1016/j.biopha.2023.115852 [doi] AB - Type 2 diabetes mellitus (T2DM) is a prevalent, chronic metabolic disease. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and aerobic exercise (AE) have shown promise in mitigating insulin resistance (IR) and T2DM. This study investigated the effects of dapagliflozin (Dapa) monotherapy and combined AE on mitochondrial quality control (MQC) in skeletal muscle and IR in T2DM rats. T2DM rats, induced by a high-fat diet/streptozotocin model, were randomly assigned to the following groups: T2DM+vehicle group (DMV), T2DM rats treated with Dapa (DMDa, 10 mg/kg/d), T2DM rats subjected to combined Dapa treatment and AE (DMDa+AE), and the standard control group (CON). Blood and skeletal muscle samples were collected after 6 weeks of intragastric administration and treadmill exercise. The results showed that DMDa monotherapy could reduce the accumulation of white adipose tissue and skeletal muscle lipid droplets and improve HOMA-IR. While the combined AE led to further reductions in subcutaneous white adipose tissue and fasting glucose levels, it did not confer additional benefits in terms of HOMA-IR. Furthermore, Dapa monotherapy enhanced skeletal muscle mitochondrial biogenesis (PGC-1alpha, NRF1, TFAM, and COX IV), mitochondrial dynamics (OPA1, DRP1, and MFN2), and mitophagy (PGAM5 and PINK1) related protein levels. Nevertheless, the combination of Dapa with AE treatment did not yield an additive effect. In conclusion, this study highlights the potential of SGLT2 inhibitors, specifically Dapa, in ameliorating IR and maintaining MQC in skeletal muscle in rats with T2DM. However, combined AE did not produce an additive effect, indicating the need for further research. CI - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Zhang, Liangzhi AU - Zhang L AD - Exercise and Metabolism Research Center, College of Physical Education and Health Sciences, Zhejiang Normal University, Jinhua, Zhejiang, China. FAU - Lin, Hengjun AU - Lin H AD - Department of Colorectal anal Surgery, Jinhua People's Hospital, Jinhua, Zhejiang, China. FAU - Yang, Xudong AU - Yang X AD - Exercise and Metabolism Research Center, College of Physical Education and Health Sciences, Zhejiang Normal University, Jinhua, Zhejiang, China. FAU - Shi, Jipeng AU - Shi J AD - Exercise Capacity Assessment and Promotion Research Center, School of Physical Education, Northeast Normal University, Changchun, Jilin, China. FAU - Sheng, Xiusheng AU - Sheng X AD - Medical Molecular Biology Laboratory, School of Medicine, Jinhua Polytechnic, Jinhua, Zhejiang, China. FAU - Wang, Lifeng AU - Wang L AD - Exercise and Metabolism Research Center, College of Physical Education and Health Sciences, Zhejiang Normal University, Jinhua, Zhejiang, China. FAU - Li, Ting AU - Li T AD - Exercise and Metabolism Research Center, College of Physical Education and Health Sciences, Zhejiang Normal University, Jinhua, Zhejiang, China. FAU - Quan, Helong AU - Quan H AD - Exercise Capacity Assessment and Promotion Research Center, School of Physical Education, Northeast Normal University, Changchun, Jilin, China. Electronic address: quanhelong@nenu.edu.cn. FAU - Zhai, Xia AU - Zhai X AD - Medical Molecular Biology Laboratory, School of Medicine, Jinhua Polytechnic, Jinhua, Zhejiang, China. Electronic address: 20211049@jhc.edu.cn. FAU - Li, Wei AU - Li W AD - Exercise and Metabolism Research Center, College of Physical Education and Health Sciences, Zhejiang Normal University, Jinhua, Zhejiang, China. Electronic address: ty1986@zjnu.edu.cn. LA - eng PT - Journal Article DEP - 20231107 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 1ULL0QJ8UC (dapagliflozin) RN - 0 (Blood Glucose) SB - IM MH - Rats MH - Animals MH - *Insulin Resistance/physiology MH - *Diabetes Mellitus, Type 2/metabolism MH - Blood Glucose/metabolism MH - Muscle, Skeletal OTO - NOTNLM OT - Aerobic exercise OT - Dapagliflozin OT - Insulin resistance OT - Mitochondrial quality control OT - Skeletal muscle OT - Type 2 diabetes mellitus COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/11/10 00:44 MHDA- 2023/12/07 12:42 CRDT- 2023/11/09 18:15 PHST- 2023/09/08 00:00 [received] PHST- 2023/10/31 00:00 [revised] PHST- 2023/11/05 00:00 [accepted] PHST- 2023/12/07 12:42 [medline] PHST- 2023/11/10 00:44 [pubmed] PHST- 2023/11/09 18:15 [entrez] AID - S0753-3322(23)01650-5 [pii] AID - 10.1016/j.biopha.2023.115852 [doi] PST - ppublish SO - Biomed Pharmacother. 2023 Dec 31;169:115852. doi: 10.1016/j.biopha.2023.115852. Epub 2023 Nov 7.